inVentiv Health Clinical has been selected for an osteoarthritis Investigational New Drug Application by IntelliCell BioSciences, Inc
inVentiv Health Clinical, a global supplier of drug development services, announced that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by IntelliCell BioSciences, Inc. IntelliCell is a regenerative medicine biotech that will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee. IntelliCell's IND study will focus on proving the company's patented technology of Ultrasonic Cavitation as a method of producing stromal vascular fraction cells as a new approach and improvement on current treatment which in the worst cases can involve surgery. About 75% of people over 70 years of age show changes consistent with osteoarthritis and symptoms such as pain, joint stiffness and joint deformities. Osteoarthritis affects more than 25 million people in the United States alone.
inVentiv Clinical will work with the principal investigator to develop investigational clinical study protocols and will serve as the CRO on trials conducted at the Pensacola Center of the Andrews Institute in Gulf Breeze, Florida. According to inVentiv Health Clinical President Raymond Hill, the company has extensive therapeutic experience in general pain and osteoarthritis programs and a focus on partnering with innovative bioscience companies.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.